Core Viewpoint - The passing of Henri Beaufour, a significant figure in Ipsen's history, is a profound loss for the company and its stakeholders, highlighting his contributions to the company's strategic direction and values established by the founding family [1][2][4]. Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in three therapeutic areas: Oncology, Rare Disease, and Neuroscience, with nearly 100 years of development experience [6]. - The company operates in over 40 countries and partners globally to deliver medicines to patients in more than 100 countries [6]. Leadership and Governance - Henri Beaufour was a long-serving member of the Board of Directors and a major shareholder, recognized for his dedication and contributions to Ipsen's growth [4]. - The Board of Directors and Executive Leadership Team expressed their condolences to the Beaufour family and reaffirmed their commitment to continue pursuing the company's strategic priorities [2][5]. Shareholder Intent - Beech Tree and Highrock, as controlling shareholders, reiterated their intent to act in the best interests of the Ipsen group and support its ongoing development [3].

Core Insights - GENFIT reported its third quarter 2025 financial results, highlighting a focus on developing treatments for rare and life-threatening liver diseases, particularly Acute on-Chronic Liver Failure (ACLF) [1][22] Financial Performance - As of September 30, 2025, the company's cash and cash equivalents increased to €119.0 million from €107.5 million as of June 30, 2025, and €81.8 million as of December 31, 2024 [2][10] - Revenue for the first nine months of 2025 was €39.2 million, a decrease from €59.7 million in the same period of 2024 [5] - The revenue was primarily driven by a Licensing and Collaboration Agreement with Ipsen, which included €12.6 million in royalty revenue and €26.5 million in milestone revenue from pricing and reimbursement approvals for Iqirvo (elafibranor) in three major European markets [6][10] Pipeline Development - The company is advancing its ACLF pipeline, with several programs in various stages of development: - G1090N is undergoing a Phase 1 First-in-Human study, with safety data expected by the end of 2025 [7] - SRT-015 aims to improve formulation for increased exposure, with a potential first-in-human trial in the second half of 2026 [7] - CLM-022 is in experiments to confirm therapeutic efficacy, with a first-in-human trial potentially starting in the first half of 2027 [8] - VS-02-HE is being developed as an oral formulation targeting gut ammonia production, with a first-in-human trial expected in the second half of 2027 [9] - GNS561 is in a Phase 1b clinical trial for cholangiocarcinoma, with data readout expected by the end of 2025 [11] Market Position - Iqirvo (elafibranor) continues to show solid growth in both U.S. and European markets for Primary Biliary Cholangitis (PBC), as reported by Ipsen [13]

Core Insights - GENFIT presents promising preclinical data on investigational drug G1090N, a novel formulation of nitazoxanide (NTZ), aimed at treating acute-on-chronic liver failure (ACLF) [1][9] - The drug is designed to optimize dose-response and provide dosing flexibility for patients with varying degrees of renal or hepatic impairment [1] Preclinical Findings - Preclinical studies indicate that NTZ has beneficial effects on systemic inflammation and organ function in ACLF disease models, showing a reduction in inflammatory cytokines and rapid restoration of hepatic and renal functions [2][3][6] - The efficacy of NTZ was demonstrated when administered post-ACLF trigger, highlighting its potential as a therapeutic approach for ACLF [3][4] Clinical Development - A Phase 1 First-in-Human study is currently underway, with safety data and initial efficacy signals expected by the end of 2025 [4][6] - Positive results from the ongoing study could lead to further clinical development and a potential Phase 2 proof-of-concept study in the first half of 2026 [2][6] Company Overview - GENFIT is a biopharmaceutical company focused on rare and life-threatening liver diseases, with a diverse R&D portfolio targeting conditions such as ACLF, cholangiocarcinoma, and urea cycle disorders [5][6] - The company has a history of successful drug development, including the accelerated approval of Iqirvo® (elafibranor) for Primary Biliary Cholangitis [5]

Core Points - The total number of shares composing the share capital as of October 31, 2025, is 83,814,526 [1] - The gross total of voting rights is 132,047,385, while the net total of voting rights is 130,726,702 [1][2] - There exists a statutory clause that requires the declaration of threshold crossing in addition to the legal thresholds [1] Summary by Category Share Capital - As of October 31, 2025, the total number of shares is 83,814,526 [1] Voting Rights - The gross total of voting rights is reported as 132,047,385, which includes shares with double voting rights and treasury shares [1][2] - The net total of voting rights, excluding shares without voting rights, is 130,726,702 [1][2] Regulatory Compliance - A statutory clause mandates the declaration of threshold crossing, complementing the legal thresholds [1]

Core Insights - Ipsen announced new data on IQIRVO for Primary Biliary Cholangitis (PBC) from the ELATIVE trial, to be presented at The Liver Meeting 2025 [1] Group 1: Clinical Trial Results - Interim data from the ELATIVE trial showed that IQIRVO led to sustained improvements in cholestasis biomarkers and stabilization of fibrosis markers over three years in 115 patients [2] - At week 182, 72% of patients on IQIRVO maintained a biochemical response, with a 47% reduction in alkaline phosphatase (ALP) from baseline [2] - Improvements in fatigue and pruritus symptoms were consistent, with a well-characterized safety profile and no new safety signals identified [2][4] Group 2: Expert Commentary - Dr. Cynthia Levy emphasized the importance of long-term treatment data for PBC, noting that IQIRVO shows effective treatment with a reassuring safety profile [3] - Sandra Silvestri highlighted IQIRVO's potential to manage disease progression markers and improve quality of life for PBC patients [4] Group 3: Mechanistic Insights - Further analysis from the ELATIVE trial indicated a relationship between changes in fatigue-associated proteins and reported fatigue outcomes in patients treated with IQIRVO [3] - The data suggests that IQIRVO, as a PPAR α/δ agonist, may modulate pathways involved in energy metabolism and mitochondrial function, addressing fatigue in PBC patients [3][6] Group 4: Trial Design and Background - The ELATIVE trial is a Phase III, multi-center, randomized, double-blind, placebo-controlled study evaluating elafibranor 80mg once daily versus placebo for PBC patients with inadequate response to ursodeoxycholic acid (UDCA) [5] - The trial enrolled 161 patients, with ongoing open-label long-term extension [5] Group 5: Product Information - IQIRVO (elafibranor) is an oral PPAR agonist that improves cholestasis and has anti-inflammatory effects, granted Breakthrough Therapy Designation by the FDA in 2019 [7] - It received accelerated approval from the FDA in June 2024 and conditional approval from the EMA and UK MHRA in late 2024 for treating PBC [7] Group 6: Disease Context - Primary Biliary Cholangitis is a rare autoimmune liver disease affecting approximately 100,000 people in the US and 165,000 in Europe, primarily women [8]

Core Insights - GENFIT is participating in the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, showcasing its commitment to addressing rare and life-threatening liver diseases [1][10] Pipeline Developments - GENFIT will present new data on its lead program G1090N, a reformulation of nitazoxanide, focusing on its efficacy in treating Acute on-Chronic Liver Failure (ACLF) [2] - The company will also present data on SRT-015, an ASK1 inhibitor that reduces systemic inflammation and promotes immune defense mechanisms in ACLF models [3] - Additional presentations will cover CLM-022, an NLRP3 inflammasome inhibitor, and the effects of VS-01 on systemic inflammation and liver injury, although VS-01 has been discontinued in ACLF [3] Real-World Evidence and Biomarkers - An oral presentation will highlight real-world evidence characterizing patients admitted for acute decompensation, emphasizing management differences [4] - Posters will present new data on biomarkers for cirrhosis, including the effectiveness of single circulating biomarkers sVCAM-1 and TSP2 in detecting fibrosis progression [7] Collaborations and Additional Data - Ipsen will present data on Iqirvo® (elafibranor) in Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC), supporting its efficacy and safety profile [11] - The data presented will underscore Iqirvo®'s potential in addressing disease progression and symptom burden in rare cholestatic liver diseases [8] Company Overview - GENFIT is dedicated to improving the lives of patients with rare liver diseases and has a strong focus on ACLF and related conditions [10][12] - The company has a rich history in liver disease research and has achieved accelerated approval for Iqirvo® in multiple jurisdictions [13][14]

Core Insights - Ipsen is acquiring ImCheck Therapeutics for €350 million ($406.6 million) with potential total transaction value reaching €1 billion ($1.16 billion) based on regulatory milestones and sales targets [1][2][3] Group 1: Transaction Details - The acquisition will be executed by Ipsen SAS' fully owned subsidiary and is expected to close by the end of Q1 2026, pending regulatory approvals [2] - Legal counsel for Ipsen is provided by Allen & Overy Shearman, while ImCheck has engaged Centerview Partners as its exclusive financial advisor [2][3] Group 2: Focus of Acquisition - The primary focus of the acquisition is ImCheck's ICT01, a Phase I/II program targeting acute myeloid leukaemia patients not suitable for intensive chemotherapy [3] - ICT01 received orphan drug status from both the European Medicines Agency and the US Food and Drug Administration in July 2025 [3] Group 3: Strategic Implications - Ipsen's CEO highlighted the acquisition as an opportunity to expand its oncology pipeline and emphasized confidence in advancing ICT01 into a Phase IIb/III trial in 2026 [4]

Core Insights - Ipsen has reported strong sales growth for the year-to-date and third quarter of 2025, with total sales reaching €2,734.8 million, a 9.6% increase compared to the same period in 2024 [2][7] - The company has upgraded its full-year financial guidance, anticipating total sales growth of around 10.0% at constant exchange rates (CER), up from previous guidance of greater than 7.0% [4][8] Sales Performance - Oncology sales increased by 4.5% year-to-date, reaching €1,912.0 million, while third-quarter sales were €624.0 million, up 3.3% [2] - Rare Disease sales saw a significant rise of 97.0% year-to-date, totaling €255.4 million, with third-quarter sales of €102.0 million, reflecting a 100.8% increase [2] - Neuroscience sales grew by 5.8% year-to-date to €567.3 million, with third-quarter sales of €188.9 million, up 3.9% [2] Pipeline and Acquisitions - Ipsen announced positive data from the Phase II LANTIC trial for IPN10200, a long-acting molecule in aesthetics, and plans to present this data at a scientific conference in H1 2026 [3][5] - The company has proposed the acquisition of ImCheck Therapeutics, which will enhance its oncology pipeline with a first-in-class asset [9][10] Regulatory Approvals - Ipsen received regulatory approval for Bylvay® in Japan for treating pruritus associated with progressive familial intrahepatic cholestasis (PFIC) [6] - The company also obtained European Commission approval for Cabometyx® in advanced neuroendocrine tumors [6] Financial Guidance - The updated financial guidance includes a core operating margin of around 35.0% of total sales, an increase from prior guidance of greater than 32.0% [8] - The company expects an adverse impact of around 3% on total sales from currency fluctuations based on September 2025 exchange rates [8][18]

Core Points - Ipsen has announced a definitive agreement to acquire ImCheck Therapeutics, a French biotechnology company specializing in next-generation immuno-oncology therapies, focusing on the ICT01 program for treating acute myeloid leukemia (AML) [1][5][6] - The acquisition aims to enhance Ipsen's oncology R&D portfolio and is expected to facilitate the launch of a Phase IIb/III trial for ICT01 in 2026, leveraging promising data from ongoing clinical trials [3][6] Transaction Details - The acquisition involves a payment of €350 million at closing, with potential total payments reaching up to €1 billion contingent on regulatory approvals and sales milestones [5][6] - The transaction is expected to be finalized by the end of Q1 2026, subject to customary closing conditions [7] Clinical Program Insights - ICT01 is a first-in-class monoclonal antibody targeting BTN3A, showing high therapeutic response rates in ongoing Phase I/II trials, particularly for patients ineligible for intensive chemotherapy [2][3][6] - The EVICTION trial data indicated that the combination of ICT01 with venetoclax and azacitidine resulted in nearly double the response rate compared to historical data for standard care [3][6] Company Background - Ipsen is a global biopharmaceutical group focused on developing innovative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of experience in drug development [11] - ImCheck Therapeutics is developing a new generation of immunotherapeutic antibodies targeting butyrophilins, with the potential to transform treatments in oncology and other fields [12][14]

Core Viewpoint - Ipsen has entered into a definitive share purchase agreement to acquire ImCheck Therapeutics, focusing on the development of next-generation immuno-oncology therapies, particularly the lead program ICT01 for acute myeloid leukemia (AML) patients who cannot tolerate intensive chemotherapy [1][3]. Company Overview - Ipsen is a global biopharmaceutical company dedicated to transformative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of development experience [11]. - ImCheck Therapeutics is a private French biotechnology company developing immunotherapeutic antibodies targeting butyrophilins, with a focus on enhancing the immune response against cancer [13][14]. Acquisition Details - The acquisition involves a payment of 350 million euros at closing, with potential total consideration up to 1 billion euros based on regulatory approvals and sales milestones [5][8]. - The transaction is expected to close by the end of Q1 2026, pending regulatory approvals [6]. Clinical Program Focus - The lead program ICT01 is a first-in-class monoclonal antibody targeting BTN3A, which has shown promising interim data in the Phase I/II EVICTION trial for AML, achieving high treatment responses [3][8]. - ICT01 is designed to activate γ9δ2 T cells, enhancing the immune response against tumors, and has received Orphan Drug Designations from both the U.S. FDA and European Medicines Agency [1][10]. Market Need - There is a significant unmet medical need for new therapies in AML, particularly for patients who are unfit for intensive chemotherapy, highlighting the urgency for innovative treatments [2].